Accession Number ADA575590
Title Harnessing GPR17 Biology for Treating Demyelinating Disease.
Publication Date Oct 2011
Media Count 7p
Personal Author N. Karandikar V. Kashi
Abstract The overarching hypothesis of this project is that GPR17 signaling results in blockade of remyelination in neuroinflammatory lesions. We thus predict that GPR17 could serve as an important target for promoting remyelination in these lesions. The specific aims of this study are: (1) To delineate the role of GPR17 in murine models of demyelinating diseases; and (2) To test the therapeutic potential for GPR17 agonists and antagonists in two models of multiple sclerosis. Our studies conducted during the first year of the project demonstrate that GPR17-deficient mice developed less severe disease and recovered faster from paralysis. Moreover, these mice showed reduced CNS- targeted pathogenic immune responses. These results provide us a strong basis to pursue drug-based treatment for this disease during the next year of the project as outlined in the original proposal and SOW.
Keywords Central nervous system
Clinical medicine
Demyelinating diseases
Diseases
Immunity
Ms(Multiple sclerosis)
Nerve fibers
Pharmacological antagonists
Reduction
Remyelination
Response(Biology)
Sheaths(Anatomy)
Targets
Therapy


 
Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
57Q - Pharmacology & Pharmacological Chemistry
57W - Stress Physiology
Corporate Author Texas Univ. Southwestern Medical School at Dallas.
Document Type Technical report
Title Note Annual rept. 8 Sep 2010-7 Sep 2011.
NTIS Issue Number 1319
Contract Number W81XWH-10-1-0721

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader